Immunology

Success for Virtual Summit on Cancer and Immunology Research – SelectScience

Science industry comes together online to share knowledge and provide technology solutions for cancer and immunology research

Thousands of scientists and scientific manufacturers from across the globe have come together online at the SelectScienceVirtual Summit on Cancer and Immunology Research, as COVID-19 forces the postponement of key events in the science industry calendar.

The SelectScienceVirtual Summits offer a crucial platform for the science industry to continue to connect, share knowledge and provide technology solutions in order to advance science and health at this critical time.

With more than 9,400 total attendees of live webinar presentations and virtual exhibit booths over 3 days of lastweeks Virtual Summit on Cancer and Immunology Research, the event featured talks by eminent speakers, technology workshops, video interviews, virtual exhibitor booths featuring leading brands, product and application news, as well as live Q&As and the first online Scientists' Choice Awards event.

With 31presentations, the most popular drew crowds of 450+ live viewers, far more than most physical shows. The event content reached over a further 780,000people online as word quickly spread on social media.

SelectScience Editor-in-Chief and Publisher, Kerry Parker, said: Our new Virtual Summits are designed to support the industry at this difficult time to ensure communication and collaboration continues to flourish. Weve been delighted by the response from across the industry.

Virtual Summit on Cancer and Immunology Research 2020 attendee breakdown by industry

Speakers at the Summit includedDr. Amanda Hummon, associate professor of chemistry and biochemistry at the Ohio State University, Prof. Steve Conlan, professor of molecular and cell biology, University of Swansea, Dr. Bruno Sainz, Ramn y Cajal Investigator, Autnoma University of Madrid, Dr. Marzia Del Re, pharmacogenetics lab associate director, University of Pisa, Greg Poore, MD/PhD Candidate in the lab of Prof. Rob Knight, University of California School of Medicine, Dr. M. Laura Martin, Ex Vivo Models Director, Englander Institute for Precision Medicine, Weill Cornell Medical College, Dr. Herve Tiriac, assistant research scientist, University of California, Dr. Aram Chung, associate professor, Korea University and University of York scientists, Dr. Peter O'Toole, head of imaging and cytometry, Dr. William Brackenbury, senior lecturer in biomedical sciences, and Dr. Nidhi Dey, postdoctoral research associate.

A number of manufacturers also presentedinformation the latest technologies available to the field, including Bio-Rad, BD Biosciences, Fluidigm Corporation, Sony Biotechnology Inc., Nexcelom Bioscience, ForteBio, Sartorius Group, GenScript, Indica Labs, QIAGEN, Analytik Jena AG, Streck Inc., BioAgilytix, MicroGEM, Twist Bioscience, Molecular Devices, PHCbi, INTEGRA Biosciences. All presentations are now availableto view on demand.

Headline themes up for discussion included topics from COVID-19 and CAR T-cell therapy to CRISPR technology, liquid biopsies, and the microbiome.

Great scientific advances come through collaboration and joint effort. Participating in the summit allows us to share our most recent advances in cancer immunotherapy said Prof. Conlan, University of Swansea Interestingly this event will be attended by more people than a physical meeting would, so it expands the opportunity to meet new researchers and businesses, which will only serve to grow global collaboration.

Dr. Peter OToole, head of imaging and cytometry, University of York, said: It was another great opportunity to introduce technologies that we are involved with, and better still we managed to bring William Brackenbury and Nidhi Dey in to talk about how they were applying these technologies to their exciting science. The talks are now available to watch on demand: I can actually share this with my group that couldnt attend at the time. It was so digestible in the short slots that we had; it makes it very approachable, so we are also encouraging others to tune in afterwards, Dr. OToole concluded.

The Virtual Summit also saw the first online Scientists Choice Awards presentation, with scientists and industry leaders joining together to celebrate the most loved life sciences technologies and SelectScience content from the previous year. The winner of Best New Life Sciences Product of 2019, as voted for by scientists worldwide, was the DeNovix CellDrop Cell Counter. The 10 latest products to earn a SelectScience Seal of Quality were also announced during the online event.

Forthcoming SelectScience Virtual Summits include:

Forthcoming event-themed Webinar Seriesinclude:

SelectScience Virtual Summits and Webinar Series available to watch on demand include:

Manufacturers should contactsalesteam@selectscience.nettoday for further information or to book booth space.

All presentations from Virtual Summit on Cancer and Immunology Research 2020 are now available to watch on demand>>

More here:
Success for Virtual Summit on Cancer and Immunology Research - SelectScience

Immunology

Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases – BioSpace

SAN DIEGO, May 19, 2020 /PRNewswire/ -- Vividion Therapeutics, a biotechnology company discovering and developing highly selective small molecule medicines that drug traditionally inaccessible targets, today announced that it has entered into an exclusive worldwide option and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) to leverage its proteomics screening platform and proprietary small molecule library to target novel E3 ligases, as well as a range of oncology and immunology therapeutic targets. Roche has the exclusive right to license resulting compounds at different stages of development.

E3 ligases are an important class of proteins responsible for directing target proteins to the proteasome for degradation. Small molecules directed to novel E3 ligases with potentially differentiated properties, such as tissue-restricted bioactivity or stronger target recognition, have the potential to unlock a wide range of valuable therapeutic applications.

As part of the agreement, Vividion will be responsible for early drug discovery and pre-clinical development for selected programs. For a subset of such programs, Vividion has the right to conduct clinical development up to proof-of-concept with the option to share development costs and split U.S. profits and losses with Roche.

Vividion will receive $135 million in a cash upfront payment from Roche and is eligible to receive several billion dollars in payments based on the achievement of preclinical, development and commercial milestoness, as well as royalties on sales of commercialized products resulting from the collaboration.

"We are thrilled to partner with Roche, marking the second major collaboration for Vividion focused on developing small molecule drugs against promising, untapped therapeutic targets," stated Dr. Diego Miralles, Chief Executive Officer of Vividion. "This collaboration with Roche will further expand a new pillar of our pipeline focused on leveraging distinct E3 ligases to bring cutting-edge treatments to patients in need."

"Our proprietary platform has demonstrated the ability to identify molecules that can drug challenging protein classes, such as transcription factors, adaptor proteins, and E3 ligases," stated Dr. Fred Aslan, President and Chief Business Officer of Vividion. "We look forward to discovering new therapies with Roche while simultaneously advancing our wholly owned pipeline."

"Partnering is a cornerstone of Roche's research strategy to transform novel ideas into medicines. We are excited about Vividion's approach to small molecule discovery and are looking forward to working with their team to discover potential new medicines for patients with cancer and immunological diseases," said James Sabry, Global Head of Roche Pharma Partnering.

About Vividion Vividion Therapeutics, Inc. is a biotechnology company focused on transforming the future of human health through the creation of highly selective small molecule medicines that drug traditionally inaccessible targets. The company is advancing a broad, diversified pipeline of multiple, selective small molecule therapeutics for highly sought-after disease-causing target proteins in oncology and immunology. The company's cutting-edge platform was spun out of the labs of Vividion's scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. For more information, please visit http://www.vividion.com.

Contact:Nick Veomettmedia@vividion.com (858) 257-1535

View original content to download multimedia:http://www.prnewswire.com/news-releases/vividion-therapeutics-announces-drug-discovery-collaboration-with-roche-focused-on-novel-e3-ligases-301061339.html

SOURCE Vividion Therapeutics

Company Codes: OTC-PINK:RHHBY, Swiss:RO, Swiss:ROG, OTC-QX:RHHBY

Link:
Vividion Therapeutics Announces Drug Discovery Collaboration with Roche Focused on Novel E3 Ligases - BioSpace

Immunology

Ex-Northwestern professor charged in sex killing again cites immunology expertise in bid to leave jail and fig – Chicago Tribune

Prosecutors have alleged that Lathem lured his boyfriend to his high-rise apartment in Chicagos Near North neighborhood. Early on the morning of July 27, 2017, Warren stood in the doorway to the bedroom with his cellphone in hand as Lathem repeatedly stabbed Cornell-Duranleau as he slept, according to prosecutors. Lathem had asked Warren to video-record the killing, prosecutors said, but he never did.

Original post:
Ex-Northwestern professor charged in sex killing again cites immunology expertise in bid to leave jail and fig - Chicago Tribune

Immunology

Asthma linked to longer intubation time in younger COVID-19 patients – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.May 18 2020

New data suggest that asthma is associated with longer time on ventilators for hospitalized younger patients with COVID-19.

Patients with COVID-19 between the ages of 20 and 59 years old who also had asthma needed a ventilator to assist with breathing for five days more on average than non-asthmatic patients with COVID-19, according to researchers at Rush University Medical Center, who published their findings today in The Journal of Allergy and Clinical Immunology: In Practice.

Among the patients who developed severe respiratory symptoms requiring intubation (the use of a ventilator), asthma was associated with a significantly longer intubation time in the younger group of patients who would seemingly have a better disease course than patients over the age of 65."

Dr. Mahboobeh Mahdavinia, Chief of Allergy and Immunology, Department of Internal Medicine, Rush University Medical Center

"Our findings suggest that younger individuals with asthma may require extra attention, as they could develop a sustained pulmonary failure with COVID-19 infection, leading to prolonged mechanical ventilation."

Some signs and symptoms of COVID-19 are similar to worsening of asthma, which can lead to a late diagnosis of COVID-19 in asthmatics. "Therefore, we looked at a large group of patients to understand the impact of preexisting asthma on the outcome of patients with COVID-19," Mahdavinia said.

"We found that asthma and obesity are connected in COVID-19 patients, which means that obesity coupled with asthma puts a patient at a significantly higher risk. This is the first report, to our knowledge, to study the role of asthma on the outcome of COVID-19 patients."

Mahdavinia's team of physician-scientists, medical residents, basic scientists, and students used an electronic medical record algorithm created by the information services team at Rush to identify patients with asthma and COVID-19 who were either hospitalized or tested for COVID-19 at Rush between the dates of March 12 and April 3.

IBM SPSS Statistics for Windows was used for the analysis of COVID-19 outcomes in association with asthma and was adjusted for demographic variables and body mass index (BMI).

Initially, data emerged for 1,003 patients who tested positive for COVID-19. Complete data on demographic variables, asthma, and COVID-19 management was available in 935 patients, who were used for analysis. Overall, 241 were found to have an established diagnosis of asthma, which was broken into three groups by age range.

Asthma was significantly associated with longer intubation time in patients between 18 and 49 years of age and between 50 and 64 years of age, but not in the age group 65 years of age and older.

The duration of hospitalization was longer among patients with a history of asthma compared to those without this history in patients aged 50 to 64 years, but not in the younger or older age groups.

The patients aged 50 to 64 on average spent two more days in the hospital than the non-asthmatics in this age group.

Asthma was not associated with a higher rate of death or with acute respiratory distress syndrome among COVID-19 patients.

"In other studies, both obesity and gender have been shown to affect COVID-19 hospitalization," said Mahdavinia. "In our study, asthma was also associated with female gender and higher BMI."

The analysis, which was adjusted for both obesity and gender, indicates that asthma is independently linked to the number of times patients needed to be on ventilators.

"We were able to confirm asthma in prior clinical documentation among 73% of patients, but some cases were self-reported upon screening. We think that patients with a history of asthma may have sought out COVID-19 testing more than others due to concern and overlapping symptoms," Mahdavinia said.

Source:

Journal reference:

Mahdavinia, M., et al (2020) Asthma prolongs intubation in COVID-19. Journal of Allergy and Clinical Immunology: In Practice. doi.org/10.1016/j.jaip.2020.05.006.

See the rest here:
Asthma linked to longer intubation time in younger COVID-19 patients - News-Medical.Net

Immunology

BetterLife Pharma Announces Appointment of Dr. Eleanor Fish, a leading expert on interferon activity – PharmiWeb.com

VANCOUVER, May 19, 2020 /PRNewswire/ -BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: PVOTF / FRA: NPAT) today announced that it has appointed Dr. Eleanor Fish to the Company's Scientific Advisory Board. Dr. Fish is an accomplished scientist with focus on interferon activity against variety of viruses including Covid-19, SARA, Ebola and Zika.

During the 2003 outbreak of SARS in Toronto, Dr. Fish initiated studies to investigate the therapeutic potential of interferon in SARS patients. Encouraging results have directed her group's efforts toward examining interferon activity against a number of emerging infectious diseases.

Dr. Fish is a Professor, Department of Immunology, University of Toronto, Associate Chair, International Initiatives & Collaborations, University of Toronto and Emerita Scientist, Toronto General Hospital Research Institute, University Health Network. She received a B.Sc. from the University of Manchester, U.K., an M.Phil. from King's College, University of London, U.K. and a Ph.D. from the Institute of Medical Sciences at the University of Toronto, Canada. Dr. Fish is a Fellow of the American Academy of Microbiologists and a Fellow of the African Academy of Sciences. Dr. Fish has received many international awards acknowledging her scientific achievements and has published more than 170 peer reviewed scientific papers in international journals.

She is the principle author of the most recent paper published on Friday May 15, 2020 in Frontiers of Immunology titled "Interferon-2b Treatment for COVID-19".

In the study, the authors examined the course of disease in a cohort of 77 individuals with con-firmed COVID-19 admitted to Union Hospital, Tongii Medical College, Wuhan, China, between January 16 and February 20, 2020. To the knowledge of the authors the findings presented in the study were the first to suggest therapeutic efficacy of IFN-a2b in Covid-19 disease.

The authors concluded that a Randomized Clinical Trial (RCT) is warranted in moderate cases of Covid-19 disease (not severely ill patients) and "treatment with IFN-a2b may also benefit public health measures aimed at slowing the tide of this pandemic, in that duration of viral shedding appears shortened."

Ahmad Doroudian, Chief Executive Officer of BetterLife, commented "We are excited to have Dr. Eleanor Fish on our Scientific Advisory Board. She brings valuable, up to date and the most relevant scientific and clinical experience in the study of interferon activity against Covid-19. Her group's most recent exploratory study of 77 patients conducted in Wuhan, China clearly indicated the potential effectiveness of Interferon-2b in treatment of patients with early signs of Covid-19."

Dr. Fish commented "Based on the results of our preliminary study in Wuhan, China, and emerging data from around the globe, I would argue that the 2 leading candidates for the treatment of mild moderate COVID-19 are IFN-alpha2b and remdesivir. I have joined the scientific advisory board of BLife Therapeutics to advise them on the proposed upcoming randomized clinical trials planned to start in July."

BetterLife also announced today that its Board of Directors has initiated a process to evaluate a range of strategic alternatives available to the Company (the "Strategic Review").

Subject to completion of its announced transaction with Altum Pharmaceuticals Inc. ("Altum"), the Company intends to focus its business on the treatment of Covid-19 and is looking at opportunities to maximize the value of its other existing business.

The Company has not established a definitive timeline to complete the Strategic Review and no decisions related to any strategic alternative have been reached at this time. There is no assurance that any strategic transaction or transactions will result from the Strategic Review. The Company does not intend to comment further with respect to the Strategic Review unless and until it determines that additional disclosure is appropriate in the circumstances and in accordance with the requirements of applicable securities laws.

About BLife Therapeutics Inc.

BLife Therapeutics is a wholly-owned subsidiary of BetterLife Pharma Inc. focused on the prevention of severe COVID-19 disease.

BetterLife has an agreement with Altum pursuant to which BLife Therapeutics will acquire worldwide rights (other than in Greater China, Japan and ASEAN countries) to commercialize and sell Altum's AP-003, a potential COVID-19 treatment. The completion of the transaction is subject to certain conditions precedent. See the Company's press release dated May 7, 2020 for further information.

About BetterLife Pharma Inc.

BetterLife Pharma Inc. is a science-based innovative medical wellness company aspiring to offer high-quality preventive and self-care products to its customers. For further information please visit abetterlifepharma.com

Cautionary Note

The Company is not making any express or implied claims that Altum's AP-003 or any other product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time. Further, the safety and efficacy of Altum's AP-003 are under investigation and market authorization has not yet been obtained.

Cautionary Note Regarding Forward-Looking Statements

Except for historical information, the matters set forth above may be forward-looking statements that involve risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to complete the transaction with Altum or to meet obligations under the agreement with Altum, the failure of Altum to complete clinical trials or to have success in such trials, the failure of Altum to secure and/or enforce patent protection for AP-003, the failure of Altum to secure exclusive rights from third parties, the failure of the Company to secure financing needed to carry out the plans set out herein, the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of BetterLife's products, statements with respect to internal expectations, the competitive environment within the industry, the ability of BetterLife to commence and expand its operations, the level of costs incurred in connection with BetterLife's operational efforts, economic conditions in the industry, pandemics, and the financial strength of BetterLife's future customers and suppliers. Reliance should not be placed on forward-looking statements, as they involve known and unknown risks, uncertainties and other factors that may cause the actual results to differ materially from the anticipated future results expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those set forward in the forward-looking statements include, but are not limited to: our ability to obtain, on satisfactory terms or at all, the capital required for research, product development, operations and marketing; general economic, business and market conditions; our ability to successfully and timely complete clinical studies; product development delays and other uncertainties related to new product development; our ability to attract and retain business partners and key personnel; the risk of our inability to profitably commercialize our proposed products; the risk that our proposed clinical trials will not be launched in a timely manner (or at all) or if launched yield positive results or that we will not obtain regulatory market approvals for our products; the extent of any future losses; the risk of our inability to establish or manage manufacturing, development or marketing collaborations; the risk of delay of, or failure to obtain, necessary regulatory approvals and, ultimately, product launches; dependence on third parties for successful commercialization of our products; inability to obtain product and raw materials in sufficient quantity or at standards acceptable to health regulatory authorities to commence and complete clinical trials or to meet commercial demand; the risk of the termination or conversion of our license with Altum or our inability to enforce our rights under our license with Altum; our ability to obtain patent protection and protect our intellectual property rights; commercialization limitations imposed by intellectual property rights owned or controlled by third parties; uncertainty related to intellectual property liability rights and liability claims asserted against us; the impact of competitive products and pricing; and future levels of government funding; additional risks and uncertainties, many of which are beyond our control.

Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise

View original content:http://www.prnewswire.com/news-releases/betterlife-pharma-announces-appointment-of-dr-eleanor-fish-a-leading-expert-on-interferon-activity-against-covid-19-to-its-advisory-board-301061242.html

SOURCE BetterLife Pharma Inc.

More:
BetterLife Pharma Announces Appointment of Dr. Eleanor Fish, a leading expert on interferon activity - PharmiWeb.com

Immunology

If youve had a common cold before you might be protected against coronavirus, experts discover – The Sun

HAVING a common cold can help fight coronavirus - raising hopes some have a degree of protection, experts claim.

Scientists have discovered cells that can attack Covid-19 in the bloodstream of people who have only ever had common colds before - all of which are caused by other strains of coronavirus.

They believe this may explain why some are more severely affected by the bug than others.

However, the researchers from the La Jolla Institute for Immunology in California, warn that their findings are yet to be proven outside of a laboratory.

Their study,published in the journal Cell, looked at immune cells - known as T-cells - which differ from the B-cells that produce antibodies.

Instead of latching onto the virus, T-cells provide another line of attack by targeting other infected cells.

Similarly to antibodies, they are made in response to an infection - and remain afterwards.

Dan Davis, professor of immunology at the University of Manchester, told the Times: When a cell is infected with a coronavirus, the viruss protein molecules are chopped up into very small pieces.

"And those small pieces are put up at the surface of the cell.

"When T-cells see these molecules that have never been in the body before they multiply, then they go and respond to those infected cells.

When T-cells see these molecules that have never been in the body before they multiply, then they go and respond to those infected cells

The researchers, from the La Jolla Institute for Immunology in California, looked at the blood of patients who had recovered from Covid-19.

They found that T-cells that they had already had in their blood responded to the new virus.

It suggests that exposure to other coronaviruses - such as the common cold or flu - had somehow primed their T cells to recognise and attack Covid-19.

The team suggest that this could influence their susceptibility to the new coronavirus, either by preventing them from getting infected or from developing severe disease.

They then looked at blood frozen in 2018 to find out if T-cells were present without Covid-19.

KIDS AT RISKIllegal Orthodox Jewish school shut as 100 kids in class despite lockdown

Comment

DAN WOOTTONCompromise with China is morally wrong - we should be asking tough questions

Live Blog

COVID CRISISCoronavirus UK LIVE: Death toll hits 35,341 as 545 more people die

virus briefingWhat did George Eustice say in today's coronavirus press conference?

VIRUS SPREADHow many coronavirus deaths and cases have there been in the UK?

DEADLY SPREADVirus rips through Latin Americas packed slums and reaches jungle tribes

WAIT A YEARPremier League clubs told they may have to play behind closed doors for a YEAR

HOCUS POTUSChina accuses Trump of 'witchcraft' after he revealed hes taking unproven drug

Latest

'HERO IN HER OWN RIGHT'Widow of astronaut & senator John Glenn dies of coronavirus at 100

STAY AFLOATHow to get a grant worth up to 25,000 from the small business grant fund

Alessandro Sette, who co-led the study, said: We saw in about half of people there was activity against Sars-CoV2."

It's promising news for vaccine developers because it is "consistent with normal, good, antiviral immunity," according to Shane Crotty, from the Center for Infectious Disease and Vaccine Research at LJI.

He said: "The types of immune responses targeted by many candidate vaccines are now shown to be the types of immune responses seen in Covid-19 cases that successfully recovered from the disease."

CORONAVIRUS CRISIS - STAY IN THE KNOW

Don't miss the latest news and figures - and essential advice for you and your family.

To receive The Sun's Coronavirus newsletter in your inbox every tea time, sign up here.To follow us on Facebook, simply 'Like' our Coronavirus page.Get Britain's best-selling newspaper delivered to your smartphone or tablet each day - find out more.

Excerpt from:
If youve had a common cold before you might be protected against coronavirus, experts discover - The Sun

Immunology

Immunology Drugs Market: Latest Industry Innovation and Key Players Informations: Thermo Fisher Scientific Inc., ERS Genomics, CRISPR THERAPEUTICS -…

New statistical research on Immunology Drugs Market 2020 will show you the latest industry insights on future trends, product, and service analysis, allowing you to penetrate deeply into the keyword market with high profitability.

The Immunology Drugs Market Report provides an in-depth analysis of the entire market. This report focuses on mainstream key players, production details, their applications, then analyzes global and major regional market potentials and benefits, opportunities, challenges, constraints, and risks.

There are a number of major competitive biotech companies that investigate the SARSs-Cov-2 genome and prepare a survival vaccine for it. Compared to the response rate to SARs/MERs, biotech organizations are investigating SARs-Cov-2 at an unprecedented rate, and a significant amount of funds are being put into R&D. For this reason, the report describes Covid19 as a major market contributor.

This report sample includes: Brief Introduction to the research report, Table of Contents (Scope covered as a part of the study), Top players in the market, Research framework (Structure of This Report), Research methodology adopted by Worldwide Market Reports.

Request a Copy of the Sample

The Top Players Covered in Immunology Drugs Market Are: Thermo Fisher Scientific Inc., ERS Genomics, CRISPR THERAPEUTICS, Merck KGaA, Editas Medicine, GE Healthcare Dharmacon Inc., Takara Bio USA

Immunology Drugs Market Outlook:

The Global Immunology Drugs Market Report gives an exclusive coverage provided for market drivers, challenges, and opportunities for country-level markets in each regional segment. This report consists of a competitive analysis of the key players operating in the market and covers in-depth data related to the markets competitive environment, recent strategies and products to support or influence the market over the next few years.

Market Drivers and the Risks Associated With the Immunology Drugs Market:

The Immunology Drugs Market is characterized by several key factors, each of which tends to play a decisive role in the growing market. Product growth has doubled with the smooth availability of a customer base that helps companies thrive around the world. On the other hand, the presence of a dynamic supply chain helped the company grow exponentially. So, with respect to the increase in Immunology Drugs Market opportunities, Immunology Drugs face serious dissatisfaction in all respects.

Some Fundamental Parameters Included in the Report:

Buy This Complete Business Report: Access Insightful Study With Over 150+ Pages, List of Tables and Figures, Profiling 20+ Companies.

The Main Geographical Regions and Markets of the Immunology Drugs Market:

If you look more closely at that region, the market is concentrated and what matters inside the file is to highlight Europe, the Middle East, and Africa, Asia Pacific, Latin America, and North America. These areas studied the intertwined traits and various possibilities, along with the prospects that could ultimately benefit the market.

Immunology Drugs Market Report Covers Following Questions:

Customization Service of the Report

Worldwide Market Reports provide reports that can be customized upon request. This report can be personalized to suit your needs. Please contact the research team so that you can receive a report tailored to your needs.

Quick Enquiryoption enables you to share your queries, in advance to procure the report. Kindly fill the form, and one of our consultants would get in touch with you to discuss the queries, and would address them.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Excerpt from:
Immunology Drugs Market: Latest Industry Innovation and Key Players Informations: Thermo Fisher Scientific Inc., ERS Genomics, CRISPR THERAPEUTICS -...

Immunology

Liver cancer: Awareness of hepatitis D must be raised – Science Codex

Of all the hepatitis viruses, D is the most poorly known. This small virus, which can only infect people already infected with HepatitisB, has so far been little studied. HepatitisD is one of the most dangerous forms of chronic viral hepatitis because of its possible progression to irreversible liver diseases (cancer and cirrhosis, in particular). Scientists from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) have studied the most serious consequence of chronic hepatitis: hepatocellular carcinoma, a particularly aggressive and often fatal liver cancer. By conducting a systematic review of the literature and a meta-analysis of all available data, they demonstrated that people infected with HepatitisD have up to three times the risk of developing hepatocellular carcinoma compared to those infected only with HepatitisB. These results, to be read in the Journal of Hepatology, plead for systematic screening of HepatitisD in patients with HepatitisB in order, on the one hand, to better manage patients and, on the other hand, to better understand the real prevalence of the disease.

There are five types of hepatitis viruses, with very different manifestations and consequences. Hepatitis A and E cause acute infections that can be severe but transient. HepatitisB, C and D, however, can become chronic and cause liver dysfunction months or even years after infection. Although HepatitisC is now well treated, HepatitisB and especially D are still difficult to control. "The most serious consequence of HepatitisB and D is hepatocellular carcinoma, explains Francesco Negro, Professor at the Department of Pathology and Immunology of UNIGE Faculty of Medicine and Head of the HUG Viropathology Unit. It was already known that co-infection of HepatitisB and D accelerates the progression of cirrhosis. However, to what extent co-infection of HepatitisB and D accelerates the progression towards this particularly aggressive liver cancer? This remained to be evaluated."

"To find out whether HepatitisD is even more dangerous than B, we carried out a systematic review and meta-analysis of all epidemiological studies, explains Dulce Alfaiate, a researcher at the Department of Pathology and Immunology of UNIGE Faculty of Medicine and first author of this work. To do this, we re-examined the data presented in 93 studies, representing a total of more than 100,000 patients. Although not all these studies are of similar quality, the analysis of the best of them is very clear: patients with HepatitisD have an almost threefold risk of developing hepatocellular carcinoma compared to those with HepatitisB alone. That's huge!"

At least 15 million people infected worldwide

According to World Health Organization figures, hundreds of millions of people are infected with the HepatitisB virus. In some regions, such as Polynesia and some African countries, more than 6% of the adult population is infected and the virus is largely transmitted from mother to child. Moreover, children infected at birth almost always develop the chronic form of the disease.

The HepatitisD virus in turn infects a significant proportion of HepatitisB carriers, but the extent of the problem is unknown. "Some estimates suggest that at least 15 to 20 million people are infected with HepatitisD, whereas other estimates may reach 60 million, almost double the number of people living with HIV worldwide, says Dulce Alfaiate. In the absence of systematic testing, however, it is extremely difficult to be precise." In Switzerland, an estimated 25,000 people live with HepatitisB, among whom 1,500 with HepatitisD. And this in spite of an available and effective HepatitisB vaccine.

A call for research

Apart from interferon, an antiviral and an immuno-modulator with limited effectiveness but with deleterious side effects, there is currently no treatment for HepatitisD. "In our view, the evolution towards liver cancer is grossly underestimated, Francesco Negro points out. And yet, this disease affects young patients who suffer from cirrhosis as early as the age of 25-30 years."Several ways of controlling the disease are currently being explored: Francesco Negro's laboratory is studying the epigenetic changes induced by the virus and the mechanism of giving rise to liver tumours. The authors conclude: "Our work underlines the need to improve HepatitisD screening in HepatitisB patients and the urgent need for effective antiviral therapies, such as the one against HepatitisC, which has saved the lives of millions of people since 2011."

Excerpt from:
Liver cancer: Awareness of hepatitis D must be raised - Science Codex

Immunology

MatriSys Bioscience is pleased to announce the appointment of Dr. James Mackay to its Board of Directors – GlobeNewswire

SAN DIEGO, May 19, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, is pleased to announce the appointment of Dr. James Mackay to its Board of Directors. Dr. Mackay joins the Board of Directors of MatriSys Bioscience with over 30 years of experience in the development of pharmaceuticals, and a strong record of bringing multiple drugs to market and patients. Dr. Mackay is founder, president, and CEO of Aristea Therapeutics, an immunology company focused on developing treatments for orphan diseases. Prior to founding Aristea Therapeutics, Dr. Mackay led the successful $1.2B acquisition and transition of Ardea Biosciences into AstraZeneca. He was President & CEO of Ardea Biosciences from 2013 to 2018. He set up an innovative model for Ardea that retained the biotechs independence and accountability for the development of the gout franchise while developing a collaborative relationship with the parent company, AstraZeneca.

Prior to Ardea Biosciences, Dr. Mackay was Global Product Vice President for Diabetes franchise at AstraZeneca where he played a critical role in the successful development of the AstraZeneca/Bristol-Myers Squibb diabetes alliance. He held a number of senior roles in AstraZenecas Clinical Development Function including portfolio management of all AstraZeneca Clinical resources and budget worldwide and management of AstraZenecas strategic partnerships with drug development CROs.

In addition to being a seasoned business leader, James is an experienced board member who has played a pivotal role in the San Diego biotechnology community. He currently sits on the Board and Executive Committee of CONNECT, is Vice-Chair of CONNECT and sits on the Board of Governors of BIOCOM. James is also a former Board member of the San Diego Economic Development Corporation (EDC).

On behalf of MatriSys Bioscience and the Board of Directors, I welcome James as we look forward to drawing upon his strategic, operational and clinical judgment, said Magda Marquet PhD, Chairwoman of MatriSys Bioscience. We are thrilled to team up with him at a critical time in our evolution as we advance our lead program through Phase 2. His significant insights and experience running large pharmaceutical and small biotechnology businesses will be essential while we continue to strengthen the development of our skin microbiome technology assets.

I am delighted to have the opportunity to join the MatriSys Bioscience Board of Directors at such a critical time for the company as we enter Phase 2 clinical development. The microbiome technology that underpins MatriSys is ground-breaking and I look forward to working with the management team to develop the MatriSys products through to approved drugs being prescribed to patients, said Dr Mackay.

Dr. Mackay has a BSc in Genetics and obtained a PhD in Medical Genetics from Aberdeen University, Scotland.

About MSB-01

MatriSys Bioscience is currently developing MSB-01 which is a commercially viable room-temperature stable topical formulation of freeze-driedS.hominis StrainA9 bacteria for application to the lesional skin of atopic dermatitis patients.

About MatriSys Bioscience

MatriSys Bioscienceis a clinical stage Specialty Biopharmaceutical Company focused on developing and commercializing rational microbiome therapies for the top five dermatology and skin care conditions. Our foundational microbiome therapeutics platform is based on the pioneering work of Richard L. Gallo MD PhD, Distinguished Professor and Founding Chair, Department of Dermatology at the University of California, San Diego and thehttp://gallolab.ucsd.edu/. For more information, please visithttp://www.matrisysbio.com/.

info@matrisysbio.com858.456.3919

Visit link:
MatriSys Bioscience is pleased to announce the appointment of Dr. James Mackay to its Board of Directors - GlobeNewswire

Human Behavior

Why Should Managers Study Human Behavior?

While it may seem obvious in this day and age that a companys treatment and understanding of its employees is instrumental to its success, it was not until the late 19th century and beginning of the 20th century that behavioral theorists really began to focus on how an employees behavior and motivation play a vital part in increasing an organizations productivity.

Known as behavioral management theory, this field of research looks at how the attitudes and actions of a companys workforce can directly influence its prosperity. Today, there are few who would dispute that a firms ability to thrive is inextricably linked to its employees levels of commitment, unity and satisfaction. This human-behavior-centered approach to corporate success takes the focus away from the methods of production and instead analyzes employees as integral elements who can significantly increase the profitability of a businesss services or end products.

As behavioral management theory grew in popularity, it became apparent that it was critical for skilled managers to understand their labor force if their organizations were to flourish. Managers needed to understand how their employees satisfaction levels and senses of loyalty could affect their work ethics and therefore overall productivity. No longer was it enough to see employees as small parts of a complex production process. Employees became a valuable resource that could work with managers and senior executives to promote an organizations development.

If you are thinking of taking Master of Business Administration (MBA) courses or enrolling in an online MBA program with an eye to a leadership role, it is likely that your success will depend on an in-depth understanding of what drives the people who work in your company. If you can understand what motivates an employee, you can use this knowledge to direct individual or group behaviors and attitudes to the benefit of your business.

A nuanced understanding of how human behavior functions within an organization is central to establishing a businesss goals and nurturing a workforce that can work effectively as a team to reach them.

Many MBA courses and online MBA programs are now offering courses in human behavior. Understanding what drives your employees can give your company a competitive edge because a satisfied employee is a more productive employee. When an organization understands its staff, it can set better goals and get its workforce to function at peak efficiency.

Good managers can directly influence an employees satisfaction and motivation. An MBA course in human behavior offers students a variety of perspectives on how the actions and attitudes of staff members, both as a group and as individuals, can influence an organizations productivity and profitability. A sophisticated understanding of human behavior helps managers effectively harness employee motivation.

Some online MBA programs, including the one at Southeastern Oklahoma State University (SOSU), offer courses in human behavior. The program at SOSU gives students the opportunity to develop in-depth understanding of how to direct human behavior and motivate workers to improve a companys bottom line.

Learn more about the SOSU online MBA in Management program.

Sources:

http://www.sciencedirect.com/science/article/pii/S1877042815012860

http://www.business.com/management/management-theory-of-elton-mayo/

http://smallbusiness.chron.com/examples-behavioral-approaches-business-management-39059.html

Have a question or concern about this article? Please contact us.

Read more:
Why Should Managers Study Human Behavior?